BR112021026790A2 - Composto de pirimidina-5-carboxamida - Google Patents

Composto de pirimidina-5-carboxamida

Info

Publication number
BR112021026790A2
BR112021026790A2 BR112021026790A BR112021026790A BR112021026790A2 BR 112021026790 A2 BR112021026790 A2 BR 112021026790A2 BR 112021026790 A BR112021026790 A BR 112021026790A BR 112021026790 A BR112021026790 A BR 112021026790A BR 112021026790 A2 BR112021026790 A2 BR 112021026790A2
Authority
BR
Brazil
Prior art keywords
pyrimidine
carboxamide compound
compound
carboxamide
formula
Prior art date
Application number
BR112021026790A
Other languages
English (en)
Inventor
Ruano Plaza Gema
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of BR112021026790A2 publication Critical patent/BR112021026790A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48Two nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

composto de pirimidina-5-carboxamida. a presente invenção refere-se a um composto da fórmula ou um sal farmaceuticamente aceitável do mesmo, e métodos para usar este composto para tratar diabetes mellitus do tipo 2.
BR112021026790A 2019-08-06 2020-07-31 Composto de pirimidina-5-carboxamida BR112021026790A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19382686 2019-08-06
EP19382744 2019-09-02
PCT/US2020/044394 WO2021025975A1 (en) 2019-08-06 2020-07-31 Pyrimidine-5-carboxamide compound

Publications (1)

Publication Number Publication Date
BR112021026790A2 true BR112021026790A2 (pt) 2022-05-10

Family

ID=71950845

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021026790A BR112021026790A2 (pt) 2019-08-06 2020-07-31 Composto de pirimidina-5-carboxamida

Country Status (13)

Country Link
US (1) US20220274933A1 (pt)
EP (1) EP4010324B1 (pt)
JP (1) JP7261349B2 (pt)
KR (1) KR20220046564A (pt)
CN (1) CN114364659A (pt)
AU (1) AU2020326552B2 (pt)
BR (1) BR112021026790A2 (pt)
CA (1) CA3145694A1 (pt)
ES (1) ES2963560T3 (pt)
IL (1) IL290345A (pt)
MX (1) MX2022001413A (pt)
WO (1) WO2021025975A1 (pt)
ZA (1) ZA202200234B (pt)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI681952B (zh) * 2011-04-22 2020-01-11 美商標誌製藥公司 經取代之二胺基甲醯胺及二胺基甲腈嘧啶、其組合物、及以該等治療之方法
WO2013078468A1 (en) * 2011-11-23 2013-05-30 Portola Pharmaceuticals, Inc. Selective kinase inhibitors
JP7359439B2 (ja) 2017-03-30 2023-10-11 ザ ボード オブ レジェンツ オブ ザ ユニバーシティ オブ テキサス システム ニコチンアミドn-メチルトランスフェラーゼ(nnmt)のキノリン由来小分子阻害剤及びその使用
US20230159470A1 (en) * 2020-02-14 2023-05-25 President And Fellows Of Harvard College Inhibitors of nicotinamide n-methyltransferase, compositions and uses thereof

Also Published As

Publication number Publication date
AU2020326552A1 (en) 2022-02-24
CN114364659A (zh) 2022-04-15
WO2021025975A1 (en) 2021-02-11
KR20220046564A (ko) 2022-04-14
EP4010324A1 (en) 2022-06-15
MX2022001413A (es) 2022-03-29
ES2963560T3 (es) 2024-03-27
IL290345A (en) 2022-04-01
EP4010324B1 (en) 2023-09-06
ZA202200234B (en) 2023-07-26
AU2020326552B2 (en) 2023-05-11
AU2020326552A8 (en) 2022-03-31
US20220274933A1 (en) 2022-09-01
CA3145694A1 (en) 2021-02-11
JP7261349B2 (ja) 2023-04-19
JP2022543265A (ja) 2022-10-11

Similar Documents

Publication Publication Date Title
BR112021023923A2 (pt) Agonistas de receptor de peptídeo 1 similares a glucagon
DOP2020000037A (es) Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
ECSP20069418A (es) Compuestos heterocíclicos como inmunomoduladores
EA201892450A1 (ru) Ароматические сульфонамидные производные
CL2018000198A1 (es) Composiciones de arni de transtiretina (ttr) y métodos para su uso para el tratamiento o prevencion de enfermedades asociadas con ttr
EA202092490A1 (ru) Модуляторы метилмодифицирующих ферментов, композиции и их применения
MX2020004534A (es) Moduladores de la vía integrada del estrés.
BR112017003658A2 (pt) composto, mistura, métodos para tratamento de uma doença e para inibição de uma glicosidase, e, composição farmacêutica.
CO2020014586A2 (es) Compuestos
EA202191991A1 (ru) Новые производные гетеротрициклического соединения и их применение
BR112017002403A2 (pt) formas de cristais de inibidores de glutaminase
EA202191519A1 (ru) Модуляторы trex1
MY194468A (en) Oxy-fluoropiperidine derivatives as kinase inhhiitor
CL2019001041A1 (es) Compuestos terapéuticos y métodos para utilizarlos.
BRPI0806789B8 (pt) composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo
EA201990400A1 (ru) Соединения и композиции и их применение
BR112019007576A2 (pt) compostos de bifenil sulfonamida para o tratamento de doenças ou transtornos renais
PE20211595A1 (es) Compuestos de 2,6-diaminopiridina
BR112019004236A2 (pt) compostos para tratar doenças associadas a uma disfunção mitocondrial
WO2016068580A3 (en) Novel pyridopyrimidinone compounds for modulating the catalytic activity of histone lysine demethylases (kdms)
MX2022000945A (es) Composicion para incrementar la expresion de pgc-1alfa.
BR112021018578A2 (pt) Compostos de heterociclil(fenil)metanol úteis no tratamento de hiperglicemia
CO2019013254A2 (es) Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias
PA8787001A1 (es) " derivados de macrolactona"
MX2020004842A (es) Compuestos heterociclicos antiinfecciosos y sus usos.